Financials
Financial year 2025
JANSSEN - CILAG INTERNATIONAL from Beerse, company number BE0461607459, closed financial year 2025 with a result of € 0 after tax. For that financial year JANSSEN - CILAG INTERNATIONAL recorded a gross margin of € 1,993 and equity of € 165,897. Compared with financial year 2024, the result moved from € 0 to € 0. Around break-even. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 23, 2026.
€ 165,897
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 0
Profit after tax over the fiscal year.
€ 6,534
▲ 22% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 103,897.
Debts at end 2025
€ 158,130
Loans from banks and other lenders, long and short.
€ 2,923
▲ 102% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 60,339
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 5,027 | € -2,883 | € -4,928 | € 1,993 | ▲ € 6,921 |
| Equity | € 165,897 | € 165,897 | € 165,897 | € 165,897 | |
| Total debts | € 1,314 | € 24,903 | € 1,448 | € 221,393 | ▲ € 219,945 |
| Cash | € 6,221 | € 10,578 | € 5,365 | € 6,534 | ▲ 22% |
| Retained profit | € 103,897 | € 103,897 | € 103,897 | € 103,897 | |
| Bank debt | € 0 | € 0 | € 0 | € 158,130 | |
| Balance sheet total | € 167,211 | € 190,800 | € 167,345 | € 387,289 | ▲ 131% |
Key figures of JANSSEN - CILAG INTERNATIONAL, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to JANSSEN - CILAG INTERNATIONAL?
What happened at JANSSEN - CILAG INTERNATIONAL in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Laurence Oster-Gozet stepped down as director. NBB
- David Van Passel stepped down as director. NBB
- Margarita Gomez Chantraine stepped down as director. NBB
- Mark Peturson stepped down as director. NBB
- Filip Elens stepped down as director. NBB
- Alwin Otten stepped down as director. NBB
- Catherine Michielsens stepped down as director. NBB
- Elena Bolaños Cascales stepped down as director. NBB
In short
From € 0 profit in 2022 to € 0 profit in 2025.
A new publication or filing at JANSSEN - CILAG INTERNATIONAL? We notify you, reason included.
Follow JANSSEN - CILAG INTERNATIONALDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by Janssen Pharmaceutica NV (99%) and Johnson & Johnson (1%).
Directors
According to the 2025 annual accounts
Laurence Oster-Gozet
Director
since 2025 · until 2031
Elizabeth (Liz) Daly
Director
since 2024 · until 2025
Filip Elens
Director
since 2024 · until 2030
Alwin Otten
Director
since 2025 · until 2030
David Van Passel
Director
since 2025 · until 2031
Peter Willems
Chairman of the board
since 2023 · until 2029
Patrick Laroche
Director
since 2020 · until 2025
since 2022 · until 2025
Catherine Michielsens
Director
since 2024 · until 2030
Elena Bolaños Cascales
Director
since 2024 · until 2030
Margarita Gomez Chantraine
Director
since 2025 · until 2031
Mark Peturson
Director
since 2025 · until 2031
Shareholders
Johnson & Johnson
1%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Turnhoutseweg 30
2340 Beerse
Turnhoutsebaan 30
2340 Beerse
Active since 20 October 1997
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0461.607.459
- VAT number
- BE 0461.607.459
- Registered office
- Turnhoutseweg 30, 2340 Beerse
- Names & denominations
- Johnson & Johnson, J&J, Johnson & Johnson Innovative Medicine, J&J Innovative Medicine · JANSSEN - CILAG INTERNATIONAL
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 6 October 1997
- Peppol
- Active · Active since 18 Dec 2025
- Activities · NACE
Overige zakelijke dienstverlening, neg